{"id":819961,"date":"2025-02-28T09:04:10","date_gmt":"2025-02-28T14:04:10","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/sarepta-therapeutics-announces-call-for-applications-for-the-8th-annual-route-79-the-duchenne-scholarship-program\/"},"modified":"2025-02-28T09:04:10","modified_gmt":"2025-02-28T14:04:10","slug":"sarepta-therapeutics-announces-call-for-applications-for-the-8th-annual-route-79-the-duchenne-scholarship-program","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/sarepta-therapeutics-announces-call-for-applications-for-the-8th-annual-route-79-the-duchenne-scholarship-program\/","title":{"rendered":"Sarepta Therapeutics Announces Call for Applications for the 8th Annual Route 79, The Duchenne Scholarship Program"},"content":{"rendered":"

<\/p>\n

Sarepta Therapeutics Announces Call for Applications for the 8th<\/sup> Annual Route 79, The Duchenne Scholarship Program<\/b><\/p>\n

\n\u2013 Applications for the 2025-2026 academic year will be accepted until May 30, 2025<\/i><\/b><\/p>\n

\n\u2013 Scholarships will be awarded to up to 20 individuals living with Duchenne muscular dystrophy and up to five siblings of individuals living with Duchenne<\/i><\/b><\/p>\n

CAMBRIDGE, Mass.–(BUSINESS WIRE<\/a>)–
\nSarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today announced the official opening of Route 79, The Duchenne Scholarship Program for the 2025-2026 academic year. Academic scholarships of up to $5,000 will be awarded to as many as 20 individuals living with Duchenne muscular dystrophy and 5 siblings of individuals living with Duchenne.<\/p>\n

\n\u201cIn the past decade, there have been significant advancements in the treatment of Duchenne muscular dystrophy that have brought a different kind of future for individuals living with Duchenne and their families,\u201d said Diane Berry, Ph.D., executive vice president and Chief Global Policy & Advocacy Officer, Sarepta. \u201cThe Route 79 Duchenne Scholarship Program celebrates these new possibilities with our Duchenne community, supporting their educational aspirations as young adults. On behalf of Sarepta and the selection committee, we\u2019d like to invite students who live with Duchenne or have a sibling who lives with Duchenne to apply as they pursue their educational goals for the year. We\u2019re looking forward to meeting this year\u2019s applicants and paving the way for these Route 79 scholars as they begin the next chapter of their academic journeys.\u201d<\/p>\n

\nTo apply for a scholarship through the Route 79 program, applicants must be accepted to or enrolled in an accredited college or university, or a trade, technical or vocational school located in the United States. Only applicants diagnosed with Duchenne or applicants who have a sibling diagnosed with Duchenne are eligible for the program. College seniors or college graduates accepted to or enrolled in graduate school are also eligible to apply. Previous recipients of Route 79 scholarships may apply for the 2025 Scholarship Program; however, applicants may only receive a Route 79 scholarship up to four times. The selection of awardees is made by an independent committee, without consideration to and blinded as to whether an applicant was previously, is currently, or expects to be in the future, undergoing treatment with a Sarepta product or investigational therapy.<\/p>\n

\nApplications will be accepted until Friday, May 30, 2025, at 11:59 p.m. PDT. Recipients will be notified prior to August 2025, and awards will be distributed directly to the school, college or university in time for fall 2025 enrollment. Students may learn more about the program, application criteria, and how to apply by visiting Sarepta.com\/route79<\/a>.<\/p>\n

About Route 79, The Duchenne Scholarship Program
\n
<\/i><\/b>The Route 79 program is designed to help students living with Duchenne and siblings of individuals living with Duchenne pursue their post-secondary educational goals. Scholarship recipients are chosen by an independent committee of Duchenne community members based on an applicant\u2019s academic and community involvement, personal essay, and recommendation letter. The underlying cause of Duchenne is a difference in the gene coding for dystrophin. Dystrophin is an essential protein that plays a pivotal role in muscle structure, function and preservation. The numerical significance of the scholarship\u2019s name, Route 79, ties to the 79 exons of the dystrophin gene. For more information, visit sarepta.com\/route79<\/b><\/a>.<\/p>\n

About Sarepta Therapeutics
\n<\/b>
<\/strong><\/i>Sarepta is on an urgent mission: engineer precision genetic medicine for rare diseases that devastate lives and cut futures short. We hold leadership positions in Duchenne muscular dystrophy (Duchenne) and limb-girdle muscular dystrophies (LGMDs) and are building a robust portfolio of programs across muscle, central nervous system, and cardiac diseases. For more information, please visit www.sarepta.com<\/a> or follow us on LinkedIn<\/a>, X<\/a>, Instagram<\/a> and Facebook.<\/a><\/p>\n

Internet Posting of Information
\n
<\/b><\/i><\/strong>We routinely post information that may be important to investors in the ‘For Investors’ section of our website at <\/i>www.sarepta.com<\/i><\/a>. We encourage investors and potential investors to consult our website regularly for important information about us.<\/i><\/p>\n

\"\"<\/p>\n

View source version on businesswire.com: <\/span>https:\/\/www.businesswire.com\/news\/home\/20250228553852\/en\/<\/a><\/span><\/p>\n

Investor Contact:
\n<\/i><\/b>
Ian Estepan
\n
617-274-4052
\n
iestepan@sarepta.com<\/a><\/p>\n

Media Contacts:
\n<\/i><\/b>
Tracy Sorrentino
\n
617-301-8566
\n
tsorrentino@sarepta.com<\/a><\/p>\n

\nKara Hoeger
\n
617-710-3898
\n
KHoeger@sarepta.com<\/a><\/p>\n

KEYWORDS:<\/b> Massachusetts United States North America<\/p>\n

INDUSTRY KEYWORDS:<\/b> Research Hispanic Pharmaceutical Philanthropy Consumer University Genetics Education Science Biotechnology Other Philanthropy Health<\/p>\n

MEDIA:<\/b><\/p>\n\n\n\n\n
Logo<\/b><\/font><\/td>\n<\/tr>\n
\"Logo\"<\/td>\n<\/tr>\n
<\/font><\/td>\n<\/tr>\n<\/table>\n","protected":false},"excerpt":{"rendered":"

Sarepta Therapeutics Announces Call for Applications for the 8th Annual Route 79, The Duchenne Scholarship Program \u2013 Applications for the 2025-2026 academic year will be accepted until May 30, 2025 \u2013 Scholarships will be awarded to up to 20 individuals living with Duchenne muscular dystrophy and up to five siblings of individuals living with Duchenne CAMBRIDGE, Mass.–(BUSINESS WIRE)– Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today announced the official opening of Route 79, The Duchenne Scholarship Program for the 2025-2026 academic year. Academic scholarships of up to $5,000 will be awarded to as many as 20 individuals living with Duchenne muscular dystrophy and 5 siblings of individuals living with Duchenne. \u201cIn the past decade, … <\/p>\n

Continue reading “Sarepta Therapeutics Announces Call for Applications for the 8th Annual Route 79, The Duchenne Scholarship Program”<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-819961","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"\nSarepta Therapeutics Announces Call for Applications for the 8th Annual Route 79, The Duchenne Scholarship Program - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/sarepta-therapeutics-announces-call-for-applications-for-the-8th-annual-route-79-the-duchenne-scholarship-program\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Sarepta Therapeutics Announces Call for Applications for the 8th Annual Route 79, The Duchenne Scholarship Program - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"Sarepta Therapeutics Announces Call for Applications for the 8th Annual Route 79, The Duchenne Scholarship Program \u2013 Applications for the 2025-2026 academic year will be accepted until May 30, 2025 \u2013 Scholarships will be awarded to up to 20 individuals living with Duchenne muscular dystrophy and up to five siblings of individuals living with Duchenne CAMBRIDGE, Mass.–(BUSINESS WIRE)– Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today announced the official opening of Route 79, The Duchenne Scholarship Program for the 2025-2026 academic year. Academic scholarships of up to $5,000 will be awarded to as many as 20 individuals living with Duchenne muscular dystrophy and 5 siblings of individuals living with Duchenne. \u201cIn the past decade, … Continue reading "Sarepta Therapeutics Announces Call for Applications for the 8th Annual Route 79, The Duchenne Scholarship Program"\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/sarepta-therapeutics-announces-call-for-applications-for-the-8th-annual-route-79-the-duchenne-scholarship-program\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2025-02-28T14:04:10+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20250228553852r1&sid=flmnd&distro=nx&lang=en\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"4 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/sarepta-therapeutics-announces-call-for-applications-for-the-8th-annual-route-79-the-duchenne-scholarship-program\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/sarepta-therapeutics-announces-call-for-applications-for-the-8th-annual-route-79-the-duchenne-scholarship-program\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Sarepta Therapeutics Announces Call for Applications for the 8th Annual Route 79, The Duchenne Scholarship Program\",\"datePublished\":\"2025-02-28T14:04:10+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/sarepta-therapeutics-announces-call-for-applications-for-the-8th-annual-route-79-the-duchenne-scholarship-program\\\/\"},\"wordCount\":726,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/sarepta-therapeutics-announces-call-for-applications-for-the-8th-annual-route-79-the-duchenne-scholarship-program\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&sty=20250228553852r1&sid=flmnd&distro=nx&lang=en\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/sarepta-therapeutics-announces-call-for-applications-for-the-8th-annual-route-79-the-duchenne-scholarship-program\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/sarepta-therapeutics-announces-call-for-applications-for-the-8th-annual-route-79-the-duchenne-scholarship-program\\\/\",\"name\":\"Sarepta Therapeutics Announces Call for Applications for the 8th Annual Route 79, The Duchenne Scholarship Program - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/sarepta-therapeutics-announces-call-for-applications-for-the-8th-annual-route-79-the-duchenne-scholarship-program\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/sarepta-therapeutics-announces-call-for-applications-for-the-8th-annual-route-79-the-duchenne-scholarship-program\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&sty=20250228553852r1&sid=flmnd&distro=nx&lang=en\",\"datePublished\":\"2025-02-28T14:04:10+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/sarepta-therapeutics-announces-call-for-applications-for-the-8th-annual-route-79-the-duchenne-scholarship-program\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/sarepta-therapeutics-announces-call-for-applications-for-the-8th-annual-route-79-the-duchenne-scholarship-program\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/sarepta-therapeutics-announces-call-for-applications-for-the-8th-annual-route-79-the-duchenne-scholarship-program\\\/#primaryimage\",\"url\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&sty=20250228553852r1&sid=flmnd&distro=nx&lang=en\",\"contentUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&sty=20250228553852r1&sid=flmnd&distro=nx&lang=en\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/sarepta-therapeutics-announces-call-for-applications-for-the-8th-annual-route-79-the-duchenne-scholarship-program\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Sarepta Therapeutics Announces Call for Applications for the 8th Annual Route 79, The Duchenne Scholarship Program\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Sarepta Therapeutics Announces Call for Applications for the 8th Annual Route 79, The Duchenne Scholarship Program - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/sarepta-therapeutics-announces-call-for-applications-for-the-8th-annual-route-79-the-duchenne-scholarship-program\/","og_locale":"en_US","og_type":"article","og_title":"Sarepta Therapeutics Announces Call for Applications for the 8th Annual Route 79, The Duchenne Scholarship Program - Market Newsdesk","og_description":"Sarepta Therapeutics Announces Call for Applications for the 8th Annual Route 79, The Duchenne Scholarship Program \u2013 Applications for the 2025-2026 academic year will be accepted until May 30, 2025 \u2013 Scholarships will be awarded to up to 20 individuals living with Duchenne muscular dystrophy and up to five siblings of individuals living with Duchenne CAMBRIDGE, Mass.–(BUSINESS WIRE)– Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today announced the official opening of Route 79, The Duchenne Scholarship Program for the 2025-2026 academic year. Academic scholarships of up to $5,000 will be awarded to as many as 20 individuals living with Duchenne muscular dystrophy and 5 siblings of individuals living with Duchenne. \u201cIn the past decade, … Continue reading \"Sarepta Therapeutics Announces Call for Applications for the 8th Annual Route 79, The Duchenne Scholarship Program\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/sarepta-therapeutics-announces-call-for-applications-for-the-8th-annual-route-79-the-duchenne-scholarship-program\/","og_site_name":"Market Newsdesk","article_published_time":"2025-02-28T14:04:10+00:00","og_image":[{"url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20250228553852r1&sid=flmnd&distro=nx&lang=en","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"4 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/sarepta-therapeutics-announces-call-for-applications-for-the-8th-annual-route-79-the-duchenne-scholarship-program\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/sarepta-therapeutics-announces-call-for-applications-for-the-8th-annual-route-79-the-duchenne-scholarship-program\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Sarepta Therapeutics Announces Call for Applications for the 8th Annual Route 79, The Duchenne Scholarship Program","datePublished":"2025-02-28T14:04:10+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/sarepta-therapeutics-announces-call-for-applications-for-the-8th-annual-route-79-the-duchenne-scholarship-program\/"},"wordCount":726,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/sarepta-therapeutics-announces-call-for-applications-for-the-8th-annual-route-79-the-duchenne-scholarship-program\/#primaryimage"},"thumbnailUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20250228553852r1&sid=flmnd&distro=nx&lang=en","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/sarepta-therapeutics-announces-call-for-applications-for-the-8th-annual-route-79-the-duchenne-scholarship-program\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/sarepta-therapeutics-announces-call-for-applications-for-the-8th-annual-route-79-the-duchenne-scholarship-program\/","name":"Sarepta Therapeutics Announces Call for Applications for the 8th Annual Route 79, The Duchenne Scholarship Program - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/sarepta-therapeutics-announces-call-for-applications-for-the-8th-annual-route-79-the-duchenne-scholarship-program\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/sarepta-therapeutics-announces-call-for-applications-for-the-8th-annual-route-79-the-duchenne-scholarship-program\/#primaryimage"},"thumbnailUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20250228553852r1&sid=flmnd&distro=nx&lang=en","datePublished":"2025-02-28T14:04:10+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/sarepta-therapeutics-announces-call-for-applications-for-the-8th-annual-route-79-the-duchenne-scholarship-program\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/sarepta-therapeutics-announces-call-for-applications-for-the-8th-annual-route-79-the-duchenne-scholarship-program\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/sarepta-therapeutics-announces-call-for-applications-for-the-8th-annual-route-79-the-duchenne-scholarship-program\/#primaryimage","url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20250228553852r1&sid=flmnd&distro=nx&lang=en","contentUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20250228553852r1&sid=flmnd&distro=nx&lang=en"},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/sarepta-therapeutics-announces-call-for-applications-for-the-8th-annual-route-79-the-duchenne-scholarship-program\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Sarepta Therapeutics Announces Call for Applications for the 8th Annual Route 79, The Duchenne Scholarship Program"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/819961","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=819961"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/819961\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=819961"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=819961"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=819961"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}